Tags

Type your tag names separated by a space and hit enter

2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.
Influenza Other Respir Viruses. 2018 07; 12(4):423-437.IO

Abstract

BACKGROUND

During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.

METHODS

We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.

RESULTS

We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively.

CONCLUSIONS

Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.

Authors+Show Affiliations

EpiConcept, Paris, France.EpiConcept, Paris, France.National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy.National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain. Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.National Centre for Epidemiology, Budapest, Hungary.The Public Health Agency of Sweden, Stockholm, Sweden.Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.Instituto Nacional de Saúde, Dr Ricardo Jorge, Lisbon, Portugal.Development for Microbiology and Immunology, Cantacuzino Institute, National Institute of Research, Bucharest, Romania.Croatian Institute of Public Health, Zagreb, Croatia.Institut Pasteur, Paris, France.National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy.National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.National Centre for Epidemiology, Budapest, Hungary.The Public Health Agency of Sweden, Stockholm, Sweden.Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.Instituto Nacional de Saúde, Dr Ricardo Jorge, Lisbon, Portugal.Development for Microbiology and Immunology, Cantacuzino Institute, National Institute of Research, Bucharest, Romania.Croatian Institute of Public Health, Zagreb, Croatia.European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.EpiConcept, Paris, France.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29125681

Citation

Kissling, Esther, et al. "2015/16 I-MOVE/I-MOVE+ Multicentre Case-control Study in Europe: Moderate Vaccine Effectiveness Estimates Against Influenza A(H1N1)pdm09 and Low Estimates Against Lineage-mismatched Influenza B Among Children." Influenza and Other Respiratory Viruses, vol. 12, no. 4, 2018, pp. 423-437.
Kissling E, Valenciano M, Pozo F, et al. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza Other Respir Viruses. 2018;12(4):423-437.
Kissling, E., Valenciano, M., Pozo, F., Vilcu, A. M., Reuss, A., Rizzo, C., Larrauri, A., Horváth, J. K., Brytting, M., Domegan, L., Korczyńska, M., Meijer, A., Machado, A., Ivanciuc, A., Višekruna Vučina, V., van der Werf, S., Schweiger, B., Bella, A., Gherasim, A., ... Moren, A. (2018). 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza and Other Respiratory Viruses, 12(4), 423-437. https://doi.org/10.1111/irv.12520
Kissling E, et al. 2015/16 I-MOVE/I-MOVE+ Multicentre Case-control Study in Europe: Moderate Vaccine Effectiveness Estimates Against Influenza A(H1N1)pdm09 and Low Estimates Against Lineage-mismatched Influenza B Among Children. Influenza Other Respir Viruses. 2018;12(4):423-437. PubMed PMID: 29125681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. AU - Kissling,Esther, AU - Valenciano,Marta, AU - Pozo,Francisco, AU - Vilcu,Ana-Maria, AU - Reuss,Annicka, AU - Rizzo,Caterina, AU - Larrauri,Amparo, AU - Horváth,Judit Krisztina, AU - Brytting,Mia, AU - Domegan,Lisa, AU - Korczyńska,Monika, AU - Meijer,Adam, AU - Machado,Ausenda, AU - Ivanciuc,Alina, AU - Višekruna Vučina,Vesna, AU - van der Werf,Sylvie, AU - Schweiger,Brunhilde, AU - Bella,Antonino, AU - Gherasim,Alin, AU - Ferenczi,Annamária, AU - Zakikhany,Katherina, AU - O Donnell,Joan, AU - Paradowska-Stankiewicz,Iwona, AU - Dijkstra,Frederika, AU - Guiomar,Raquel, AU - Lazar,Mihaela, AU - Kurečić Filipović,Sanja, AU - Johansen,Kari, AU - Moren,Alain, AU - ,, Y1 - 2018/03/14/ PY - 2017/10/16/accepted PY - 2017/11/11/pubmed PY - 2019/4/12/medline PY - 2017/11/11/entrez KW - case-control study KW - influenza KW - influenza vaccine KW - multicentre study KW - vaccine effectiveness SP - 423 EP - 437 JF - Influenza and other respiratory viruses JO - Influenza Other Respir Viruses VL - 12 IS - 4 N2 - BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. SN - 1750-2659 UR - https://www.unboundmedicine.com/medline/citation/29125681/2015/16_I_MOVE/I_MOVE+_multicentre_case_control_study_in_Europe:_Moderate_vaccine_effectiveness_estimates_against_influenza_A_H1N1_pdm09_and_low_estimates_against_lineage_mismatched_influenza_B_among_children_ L2 - https://doi.org/10.1111/irv.12520 DB - PRIME DP - Unbound Medicine ER -